Related references
Note: Only part of the references are listed.Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates
Angiolo Pierantoni et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2015)
Risk Factors for Hospital Admission with RSV Bronchiolitis in England: A Population-Based Birth Cohort Study
Joanna Murray et al.
PLOS ONE (2014)
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
Leo Swadling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients
Christian Renaud et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections
N. Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
Stefania Capone et al.
EXPERT REVIEW OF VACCINES (2013)
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Maarten O. Blanken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus
Alessandra Vitelli et al.
PLOS ONE (2013)
Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
Elissa Malkin et al.
PLOS ONE (2013)
Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine
Chin-Fen Yang et al.
VACCINE (2013)
Clinical development of Modified Vaccinia virus Ankara vaccines
Sarah C. Gilbert
VACCINE (2013)
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
Gregory M. Glenn et al.
VACCINE (2013)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection
Shelagh M. Szabo et al.
Paediatric Respiratory Reviews (2012)
Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children
David I. Bernstein et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
Stefano Colloca et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Viral vectors as vaccine platforms: deployment in sight
Christine S. Rollier et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years
Peter L. Collins et al.
VIRUS RESEARCH (2011)
CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2010)
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair et al.
LANCET (2010)
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life
Nele Sigurs et al.
THORAX (2010)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease
Matthew R. Olson et al.
JOURNAL OF IMMUNOLOGY (2007)
Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment
MK O'Shea et al.
CLINICAL INFECTIOUS DISEASES (2005)
Respiratory syncytial virus infection in elderly and high-risk adults
AR Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
RA Karron et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area
SA Deshpande et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2003)
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry
C Parnes et al.
PEDIATRIC PULMONOLOGY (2003)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Respiratory syncytial virus infections in previously healthy working adults
CB Hall et al.
CLINICAL INFECTIOUS DISEASES (2001)
Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
TG Boyce et al.
JOURNAL OF PEDIATRICS (2000)
Share Paper
